Table 2. Univariate analysis of clinical characteristics associated with local progression-free survival (LPFS), relapse-free survival (RFS), and overall survival (OS).

			LPFS		RFS		OS
Characteristics		No. of patients, n	3 year (95% CI), %	p-value†	3 year (95% CI), %	p-value†	3 year (95% CI), %	p-value†
Gender	Male	60	87.8 (78.1–97.5)	0.273	21.9 (6.6–37.2)	0.896	72.6 (59.7–85.5)	0.694
	Female	11	100 (100)		36.4 (8.0–64.8)		81.8 (59.0–100)
Age, years	<60	22	89.5 (79.2–99.8)	0.879	21.8 (4.1–39.5)	0.387	81.8 (65.7–97.9)	0.589
	≥60	49	90.7 (78.4–100)		28.8 (13.4–44.2)		71.3 (60.0–85.6)
Aetiology of LC	HBV	57	87.3 (77.2–97.4)	0.214	24.3 (11.6–37.0)	0.497	71.4 (58.2–84.7)	0.445
	Others	14	100 (100)		38.7 (12.2–65.2)		85.7 (67.4–100)
Child–Pugh Classification	A	68	89.6 (81.3–97.9)	0.665	27.5 (15.3–39.7)	0.051	76.4 (65.1–87.7)	0.034
	B	3	100 (100)		0 (–)		33.3 (0–86.6)
AFP, ng/mL	<10	43	88.8 (77.9–99.7)	0.882	33.7 (19.6–48.2)	0.098	84.2 (72.2–96.2)	0.032
	≥10	28	92.1 (82.1–100)		17.0 (0–34.6)		60.0 (39.8–80.2)
Tumour size, cm	<3	64	88.8 (80.0 -97.7)	0.426	24.6 (11.6–37.6)	0.413	74.6 (62.6–86.6)	0.697
	≥3	7	100 (100)		42.9 (6.4–79.6)		71.4 (38.0–100)
AJCC stage	I–II	66	89.3 (80.8–97.8)	0.534	25.9 (13.2–38.4)	0.658	77.8 (66.7–88.9)	0.030
	IIIA	5	100 (100)		30.0 (0–76.8)		30.0 (0–76.8)
BCLC stage	A	43	91.3 (81.5–100)	0.447	24.0 (8.8–39.3)	0.899	82.0 (69.6–94.4)	0.090
	B	28	88.6 (76.4–100)		29.9 (10.9–48.8)		61.6 (40.3–82.9)
Pre-Tx to PBT site	No	16	88.9 (68.4–100)	0.647	31.3 (8.6–54.0)	0.817	93.8 (81.9–100)	0.087
	Yes	55	90.4 (82.4–98.4)		25.7 (11.7–39.6)		68.7 (91.9–82.5)
Pre-Tx to other site	No	11	90.9 (73.9–100)	0.930	54.6 (25.2–84.0)	0.073	81.8 (59.0–100)	0.749
	Yes	60	89.8 (80.9–98.7)		22.5 (10.5–34.5)		73.5 (61.2–85.8)
Tumour response	CR	66	95.5 (89.1–100)	<0.001	28.3 (15.8–40.9)	0.046	81.1% (70.6–91.5)	<0.001
	Non-CR	5	0 (–)		0 (–)		0 (–)

Abbreviations: CI, confidence interval; CR, complete response; all others are the same as in Table 1.

^†log-rank test.